Vaxart Provides Business Update and Reports Full Year 2024 Financial Results
Vaxart (VXRT) reported its full year 2024 financial results and business updates. The company initiated a Phase 1 trial for its second-generation oral norovirus vaccine, with topline data expected by mid-2025. The company ended 2024 with $51.7 million in cash and equivalents, providing runway through Q4 2025.
Key financial metrics include:
- Net loss of $66.9 million ($0.33 per share) in 2024, improved from $82.5 million in 2023
- Revenue increased to $28.7 million in 2024, up from $7.4 million in 2023
- R&D expenses rose to $74.2 million from $68.1 million in 2023
The company continues follow-up for its COVID-19 Phase 2b 400-person sentinel cohort, though received a stop work order from the U.S. government in February 2025. Vaxart implemented a 10% workforce reduction following this order. The company is also advancing its avian influenza program with a new vaccine candidate.
Vaxart (VXRT) ha riportato i risultati finanziari e gli aggiornamenti aziendali per l'intero anno 2024. L'azienda ha avviato uno studio di Fase 1 per il suo vaccino orale di seconda generazione contro il norovirus, con dati preliminari attesi entro metà 2025. La società ha chiuso il 2024 con 51,7 milioni di dollari in contante e equivalenti, garantendo così una liquidità fino al quarto trimestre del 2025.
I principali indicatori finanziari includono:
- Perdita netta di 66,9 milioni di dollari (0,33 dollari per azione) nel 2024, migliorata rispetto ai 82,5 milioni di dollari del 2023
- Ricavi aumentati a 28,7 milioni di dollari nel 2024, rispetto ai 7,4 milioni di dollari del 2023
- Le spese per R&S sono aumentate a 74,2 milioni di dollari, rispetto ai 68,1 milioni di dollari del 2023
L'azienda continua il follow-up per il suo studio di Fase 2b su 400 persone per il COVID-19, anche se ha ricevuto un ordine di sospensione dei lavori dal governo degli Stati Uniti nel febbraio 2025. Vaxart ha implementato una riduzione del personale del 10% a seguito di questo ordine. L'azienda sta anche avanzando il suo programma sull'influenza aviaria con un nuovo candidato vaccinale.
Vaxart (VXRT) informó sobre sus resultados financieros y actualizaciones comerciales para todo el año 2024. La compañía inició un ensayo de Fase 1 para su vacuna oral de segunda generación contra el norovirus, con datos preliminares esperados para mediados de 2025. La empresa cerró 2024 con 51,7 millones de dólares en efectivo y equivalentes, lo que proporciona liquidez hasta el cuarto trimestre de 2025.
Los principales indicadores financieros incluyen:
- Pérdida neta de 66,9 millones de dólares (0,33 dólares por acción) en 2024, mejorando desde 82,5 millones de dólares en 2023
- Los ingresos aumentaron a 28,7 millones de dólares en 2024, en comparación con 7,4 millones de dólares en 2023
- Los gastos en I+D aumentaron a 74,2 millones de dólares desde 68,1 millones de dólares en 2023
La compañía continúa el seguimiento de su cohorte centinela de 400 personas en Fase 2b para COVID-19, aunque recibió una orden de detención de trabajos del gobierno de EE. UU. en febrero de 2025. Vaxart implementó una reducción del 10% en su fuerza laboral tras esta orden. La empresa también está avanzando en su programa de influenza aviar con un nuevo candidato a vacuna.
Vaxart (VXRT)는 2024년 전체 재무 결과 및 사업 업데이트를 보고했습니다. 회사는 두 번째 세대 경구 노로바이러스 백신에 대한 1상 시험을 시작했으며, 주요 데이터는 2025년 중반에 예상됩니다. Vaxart는 2024년을 5,170만 달러의 현금 및 현금성 자산으로 마감하여 2025년 4분기까지 자금을 확보했습니다.
주요 재무 지표는 다음과 같습니다:
- 2024년 순손실 6,690만 달러 (주당 0.33달러), 2023년의 8,250만 달러에서 개선됨
- 2024년 수익이 2,870만 달러로 증가했으며, 2023년의 740만 달러에서 상승
- 연구개발 비용이 2023년의 681만 달러에서 7420만 달러로 증가
회사는 COVID-19에 대한 400명 규모의 2b상 센티넬 코호트에 대한 후속 조치를 계속하고 있으나, 2025년 2월에 미국 정부로부터 작업 중지 명령을 받았습니다. Vaxart는 이 명령에 따라 10%의 인력 감축을 시행했습니다. 회사는 또한 새로운 백신 후보와 함께 조류 인플루엔자 프로그램을 추진하고 있습니다.
Vaxart (VXRT) a annoncé ses résultats financiers et ses mises à jour commerciales pour l'année entière 2024. L'entreprise a lancé un essai de phase 1 pour son vaccin oral de deuxième génération contre le norovirus, avec des données préliminaires attendues d'ici la mi-2025. La société a terminé 2024 avec 51,7 millions de dollars en liquidités et équivalents, assurant ainsi des fonds jusqu'au quatrième trimestre 2025.
Les principaux indicateurs financiers incluent :
- Perte nette de 66,9 millions de dollars (0,33 dollar par action) en 2024, améliorée par rapport à 82,5 millions de dollars en 2023
- Les revenus ont augmenté à 28,7 millions de dollars en 2024, contre 7,4 millions de dollars en 2023
- Les dépenses de R&D ont augmenté à 74,2 millions de dollars contre 68,1 millions de dollars en 2023
L'entreprise continue de suivre sa cohorte sentinelle de 400 personnes en phase 2b pour le COVID-19, bien qu'elle ait reçu un ordre d'arrêt de travail du gouvernement américain en février 2025. Vaxart a mis en œuvre une réduction de 10 % de sa main-d'œuvre à la suite de cet ordre. L'entreprise fait également progresser son programme sur la grippe aviaire avec un nouveau candidat vaccin.
Vaxart (VXRT) hat seine Finanzzahlen und Geschäftsinformationen für das gesamte Jahr 2024 veröffentlicht. Das Unternehmen hat eine Phase-1-Studie für seinen oralen Norovirus-Impfstoff der zweiten Generation gestartet, wobei die ersten Daten bis Mitte 2025 erwartet werden. Das Unternehmen schloss das Jahr 2024 mit 51,7 Millionen Dollar an Bargeld und Äquivalenten ab, was eine Finanzierung bis zum vierten Quartal 2025 sichert.
Wichtige Finanzkennzahlen sind:
- Nettoverlust von 66,9 Millionen Dollar (0,33 Dollar pro Aktie) im Jahr 2024, verbessert gegenüber 82,5 Millionen Dollar im Jahr 2023
- Umsatz stieg auf 28,7 Millionen Dollar im Jahr 2024, gegenüber 7,4 Millionen Dollar im Jahr 2023
- F&E-Ausgaben stiegen auf 74,2 Millionen Dollar von 68,1 Millionen Dollar im Jahr 2023
Das Unternehmen setzt die Nachverfolgung seiner COVID-19 Phase-2b Sentinel-Kohorte mit 400 Personen fort, erhielt jedoch im Februar 2025 eine Arbeitsstoppanordnung von der US-Regierung. Vaxart führte nach dieser Anordnung eine 10%ige Reduzierung der Belegschaft durch. Das Unternehmen treibt auch sein Programm zur Vogelgrippe mit einem neuen Impfstoffkandidaten voran.
- Revenue significantly increased to $28.7M in 2024 from $7.4M in 2023
- Net loss per share improved to $0.33 in 2024 from $0.57 in 2023
- Cash runway extends through Q4 2025 with $51.7M in cash and equivalents
- Received stop work order for COVID-19 Phase 2b trial from U.S. government
- Implemented 10% workforce reduction in early 2025
- R&D expenses increased by 9% to $74.2M in 2024
- Continued net loss of $66.9M despite revenue growth
Insights
Vaxart's 2024 financial results reveal a mixed picture. Revenue substantially increased to
The cash position of
The government's February 2025 stop work order for the COVID-19 Phase 2b trial (except for the 400-person cohort follow-up) represents a concerning development that prompted a
The norovirus vaccine program now appears to be the main focus, with Phase 1 trials initiated for second-generation constructs and potential progression to Phase 2b by late 2025, contingent on securing additional funding or partnerships. The "pending a partnership or other funding" language for advancing the norovirus program highlights the company's capital constraints despite the current cash position.
Initiated Phase 1 clinical trial evaluating its second-generation oral norovirus vaccine constructs with topline data expected as early as mid-2025
Continues per protocol follow-up for the COVID-19 Phase 2b 400-person sentinel cohort
Cash, cash equivalents and investments of
Conference call today at 4:30 p.m. ET
SOUTH SAN FRANCISCO, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced its business update and financial results for the full year 2024.
“Since our founding, Vaxart has been on a mission to transform global health with the goal of pioneering oral pill vaccines that can provide protection against common viral diseases safely and effectively,” said Steven Lo, Chief Executive Officer of Vaxart. “Developing a safe vaccine that improves convenience and reduces the risk of illness or death compared to existing options, or creates a solution where no vaccine or treatment exists, is crucial for bolstering U.S. and global public health.”
“We are making important progress on our mission by executing on our key milestones, highlighted by the initiation of our Phase 1 norovirus trial evaluating our second-generation oral vaccine candidate. We believe our second-generation candidate may be more potent than our first-generation candidate, which already demonstrated a favorable safety profile in multiple clinical trials, showed protection in a human challenge model, and elicited mucosal and systemic immunity in older adults. At the same time, we are continuing our efforts with the per protocol follow up for the 400-person sentinel cohort from our COVID-19 Phase 2b trial, and will further update on the BARDA award as events warrant,” concluded Mr. Lo.
Recent Business Highlights
Norovirus Vaccine Developments
- In March 2025, Vaxart initiated its Phase 1, open label, dose ranging clinical trial evaluating its second-generation oral norovirus vaccine constructs head-to-head against its first-generation constructs. The study will measure safety and immune parameters that have correlated to protection in the completed norovirus challenge study, with topline data expected as early as mid-2025.
- If the Phase 1 trial is successful, the next step, pending a partnership or other funding, would be to conduct a Phase 2b safety and immunogenicity study that could potentially begin as early as the second half of 2025 followed by an End of Phase 2 meeting with the U.S. Food and Drug Administration (FDA). A Phase 3 trial could then begin as early as 2026.
- In March 2025, Science Translational Medicine published the complete data from Vaxart’s Phase 1b trial of its first-generation oral pill norovirus vaccine candidate in elderly adults (55-80 years).
- Data from this study demonstrated strong and durable antibody responses and induction of norovirus-specific antibody and T cell responses, supporting the immunogenicity of the vaccine candidate in a patient population that often has age-related reductions in immune responses to injected vaccines.
COVID-19 Vaccine Developments
- In December 2024, Vaxart announced the 400-person sentinel cohort of the Phase 2b trial evaluating its COVID-19 vaccine candidate head-to-head against an approved mRNA comparator completed enrollment. Participants are monitored for up to 12 months post-vaccination to assess safety, immunogenicity, and efficacy for the sentinel cohort.
- In January 2025, an independent Data Safety Monitoring Board (DSMB) recommended the study to proceed without modifications based on initial safety assessment the sentinel cohort’s 30-day data.
- On February 21, 2025, Vaxart received an order from Advanced Technology International on behalf of the U.S. government directing that it stop work on all its efforts on the COVID-19 Phase 2b trial, with the exception that Vaxart may continue work associated with the per protocol follow-up for the 400-person cohort. Within 90 days of the order, the stop work order will either be canceled, extended, or work on this project will be terminated.
Influenza Program Developments
- Vaxart continues to advance its avian influenza program. Vaxart previously published data demonstrating protection in a preclinical model against avian influenza after oral immunization (Clin Vaccine Immunol 2013). Vaxart recently created a new avian influenza vaccine candidate to cover the latest clade 2.3.4.4b. Vaxart is in the process of conducting several preclinical studies to evaluate the new construct and preparing to manufacture it for clinical use. Vaxart intends to publish the results of the preclinical studies when complete.
Corporate Update
- In January 2025, Vaxart appointed Kevin Finney to Vaxart’s Board of Directors. Mr. Finney is a seasoned healthcare executive and experienced board member who brings decades of industry leadership experience and operational expertise.
Financial Results for the Full Year Ended December 31, 2024
- Cash, cash equivalents and investments totaled
$51.7 million as of December 31, 2024. Currently, Vaxart anticipates cash runway into the fourth quarter of 2025. After receiving the February 2025 stop work order related to the COVID Phase 2b trial, Vaxart implemented a restructuring plan that led to an approximately10% reduction of Vaxart’s workforce on a full-time equivalent basis. - Vaxart reported a net loss of
$66.9 million for the full year 2024, compared to$82.5 million for the full year 2023. Net loss per share for 2024 was$0.33 , compared to a net loss of$0.57 per share for 2023. - Revenue for the full year 2024 was
$28.7 million , compared to$7.4 million for 2023. Revenue in 2024 was primarily from government contracts related to the BARDA contracts awarded in January and June 2024. Revenue in 2023 was primarily from revenue recognized for work performed under Vaxart’s grant from the Bill & Melinda Gates Foundation and non-cash royalty revenue from increased sales of Inavir in Japan. - Research and development expenses were
$74.2 million for 2024, compared to$68.1 million for 2023. The increase is primarily due to increases in clinical trial expenses related to Vaxart’s COVID-19 vaccine candidate, an increase in manufacturing and preclinical expenses and facilities expenses, partially offset by a decrease in clinical trial expenses related to Vaxart’s norovirus vaccine candidate and a decrease in stock-based compensation expense and personnel-related costs. - General and administrative expenses were
$20.8 million for 2024, compared to$22.6 million for 2023. The decrease is primarily due to a decrease in personnel-related costs, including stock-based compensation expenses, and directors’ and officers’ insurance costs, offset by increases in severance costs, recruiting costs and other professional fees.
Conference Call
The Vaxart senior management team will host a conference call to discuss the business update and financial results for the full year 2024 today, beginning at 4:30 p.m. ET.
The conference call can be accessed using the following information:
Webcast: Click here
Date: Thursday, March 20, 2025 – 4:30 p.m. ET
Domestic: (877) 407-0832
International: (201) 689-8433
Conference ID: 13751819
Investors may submit written questions in advance of the conference call to ir@vaxart.com.
A replay of the webcast will be available for 30 days on Vaxart’s website at www.vaxart.com following the conclusion of the event.
About Vaxart
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.
Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Vaxart’s strategy, prospects, plans and objectives, results from preclinical and clinical trials, commercialization agreements and licenses, and beliefs and expectations of management are forward-looking statements. These forward-looking statements may be accompanied by such words as “should,” “believe,” “could,” “potential,” “will,” “expected,” “anticipate,” “plan,” and other words and terms of similar meaning. Examples of such statements include, but are not limited to, statements relating to Vaxart’s ability to develop and commercialize its product candidates, including its vaccine booster products; Vaxart’s expectations regarding clinical results and trial data; and Vaxart’s expectations with respect to the effectiveness of its product candidates. Vaxart may not actually achieve the plans, carry out the intentions, or meet the expectations or projections disclosed in the forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations, and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Vaxart makes, including uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement, and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates, and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from the clinical studies; that the stop work order discussed above may result in further work on the COVID-19 Phase 2b trial being terminated; decisions by regulatory authorities impacting labeling, manufacturing processes, and safety that could affect the availability or commercial potential of any product candidate, including the possibility that Vaxart’s product candidates may not be approved by the FDA or non-U.S. regulatory authorities; that, even if approved by the FDA or non-U.S. regulatory authorities, Vaxart’s product candidates may not achieve broad market acceptance; that a Vaxart collaborator may not attain development and commercial milestones; that Vaxart or its partners may experience manufacturing issues and delays due to events within, or outside of, Vaxart’s or its partners’ control; difficulties in production, particularly in scaling up initial production, including difficulties with production costs and yields, quality control, including stability of the product candidate and quality assurance testing, shortages of qualified personnel or key raw materials, and compliance with strictly enforced federal, state, and foreign regulations; that Vaxart may not be able to obtain, maintain, and enforce necessary patent and other intellectual property protection; that Vaxart’s capital resources may be inadequate; Vaxart’s ability to resolve pending legal matters; Vaxart’s ability to obtain sufficient capital to fund its operations on terms acceptable to Vaxart, if at all; the impact of government healthcare proposals and policies; competitive factors; and other risks described in the “Risk Factors” sections of Vaxart’s Quarterly and Annual Reports filed with the U.S. Securities and Exchange Commission. Vaxart does not assume any obligation to update any forward-looking statements, except as required by law.
Contact
Vaxart Media and Investor Relations:
Matt Steinberg
FINN Partners
IR@vaxart.com
(646) 871-8481
Vaxart, Inc. | ||||||||
Condensed Consolidated Balance Sheets | ||||||||
December 31, | December 31, | |||||||
2024 | 2023 | |||||||
(Unaudited) | (1) | |||||||
(in thousands) | ||||||||
Assets | ||||||||
Cash and cash equivalents | $ | 25,229 | $ | 34,755 | ||||
Short-term investments | 26,494 | 4,958 | ||||||
Accounts receivable | 5,761 | 3,008 | ||||||
Unbilled receivable from government contracts | 6,208 | - | ||||||
Prepaid expenses and other assets | 5,407 | 3,741 | ||||||
Property and equipment, net | 8,705 | 11,731 | ||||||
Prepaid clinical services, long-term | 60,116 | - | ||||||
Right-of-use assets, net | 20,404 | 24,840 | ||||||
Intangible assets, net | 3,557 | 4,289 | ||||||
Goodwill | 4,508 | 4,508 | ||||||
Total assets | $ | 166,389 | $ | 91,830 | ||||
Liabilities and stockholders’ equity | ||||||||
Accounts payable | $ | 6,963 | $ | 1,584 | ||||
Deferred government revenue | 65,400 | - | ||||||
Accrued and other liabilities | 11,817 | 5,927 | ||||||
Operating lease liability | 17,526 | 20,088 | ||||||
Liability related to sale of future royalties | 5,758 | 6,426 | ||||||
Total liabilities | 107,464 | 34,025 | ||||||
Stockholders’ equity | 58,925 | 57,805 | ||||||
Total liabilities and stockholders’ equity | $ | 166,389 | $ | 91,830 | ||||
(1) Derived from the audited consolidated financial statements of Vaxart, Inc. for the year ended December 31, 2023, included on the Form 10-K filed with the Securities and Exchange Commission on March 14, 2024. |
Vaxart, Inc. | |||||||||||
Condensed Consolidated Statements of Operations | |||||||||||
(Unaudited) | |||||||||||
Year Ended December 31, | |||||||||||
2024 | 2023 | ||||||||||
(Unaudited) | (1) | ||||||||||
(in thousands, except share and per share amounts) | |||||||||||
Revenue | $ | 28,700 | $ | 7,379 | |||||||
Operating expenses: | |||||||||||
Research and development | 74,213 | 68,142 | |||||||||
General and administrative | 20,780 | 22,584 | |||||||||
Total operating expenses | 94,993 | 90,726 | |||||||||
Operating loss | (66,293 | ) | (83,347 | ) | |||||||
Other (expense) income, net | (395 | ) | 1,143 | ||||||||
Loss before income taxes | (66,688 | ) | (82,204 | ) | |||||||
Provision for income taxes | 260 | 261 | |||||||||
Net loss | $ | (66,948 | ) | $ | (82,465 | ) | |||||
Net loss per share, basic and diluted | $ | (0.33 | ) | $ | (0.57 | ) | |||||
Shares used in computing net loss per share, basic and diluted | 202,137,531 | 144,819,781 | |||||||||
(1) Derived from the audited consolidated financial statements of Vaxart, Inc. for the year ended December 31, 2023, included on the Form 10-K filed with the Securities and Exchange Commission on March 14, 2024. |
This press release was published by a CLEAR® Verified individual.
